Related Experiment Video
Updated: May 18, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Strategies for p53 reactivation in human sarcoma
Ted R Hupp1, Richard L Hayward, Borek Vojtesek
1Institute of Genetics and Molecular Medicine, University of Edinburgh, UK. ted.hupp@ed.ac.uk
Abstract:
Emerging strategies in cancer therapeutics link the genomic mutational and proteomic landscape, allowing intelligent reasoning on target selection. In this issue of Cancer Cell, Piccinin and colleagues use this approach to demonstrate that the mesenchymal protein Twist1 inhibits p53, providing a novel target for reactivation of p53 in human sarcoma.
Insights
Emerging cancer therapies integrate genomic and proteomic data for target selection. Researchers found the mesenchymal protein Twist1 inhibits p53, offering a new therapeutic target for human sarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Cancer therapeutic strategies increasingly leverage multi-omics data, integrating genomic and proteomic information for precise target identification.
- The tumor suppressor protein p53 plays a critical role in preventing cancer, but its function is often compromised in malignant cells.
Discussion:
- This study investigates the interplay between the mesenchymal protein Twist1 and the p53 pathway in cancer.
- The research demonstrates that Twist1 actively suppresses p53 activity, highlighting a novel mechanism of oncogenesis.
Key Insights:
- The mesenchymal protein Twist1 directly inhibits the tumor suppressor p53.
- Reactivation of p53 presents a promising therapeutic strategy for human sarcoma.
Outlook:
- Targeting the Twist1-p53 interaction could lead to novel therapeutic approaches for sarcoma.
- Further research into Twist1's role in other cancers may reveal broader therapeutic applications.
More Related Videos
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Treatment Resistant Cancers

